DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of new information on its soluble CD83 (sCD83) protein program in a poster session at the 2009 American Transplant Congress, held May 30-June 3 in Boston. The poster presentation, to be made on June 2 at 5:30pm by Argos’ collaborating scientists from the University of Western Ontario, demonstrates that combination therapy with sCD83 can prolong kidney allograft survival in an animal model of transplantation, and that sCD83 attenuates pathological changes in kidney allografts, induces generation of T regulatory cells and inhibits dendritic cell maturation, all of which may contribute to immunosuppression and allograft tolerance.
